5K09

Crystal Structure of COMT in complex with a thiazole ligand

5K09 の概要

• エントリーDOI: 10.2210/pdb5k09/pdb
• 分子名称: Catechol O-methyltransferase, 5-{3-[(4-methoxyphenyl)methyl]-1H-pyrazol-5-yl}-2,4-dimethyl-1,3-thiazole, POTASSIUM ION, ... (5 entities in total)
• 機能のキーワード: methyltransferase, neurotransmitter degradation, catechol, transferase
• 由来する生物種: Rattus norvegicus (Norway Rat)
• タンパク質・核酸の鎖数: 24
• 化学式量合計: 592585.40

構造登録者

Ehler, A.,Rodriguez-Sarmiento, R.M.,Rudolph, M.G. (登録日: 2016-05-17, 公開日: 2016-09-07, 最終更新日: 2024-05-08)

主引用文献

Lerner, C.,Jakob-Roetne, R.,Buettelmann, B.,Ehler, A.,Rudolph, M.,Rodriguez Sarmiento, R.M.
Design of Potent and Druglike Nonphenolic Inhibitors for Catechol O-Methyltransferase Derived from a Fragment Screening Approach Targeting the S-Adenosyl-l-methionine Pocket.
J. Med. Chem., 59:10163-10175, 2016

PubMed Abstract: A fragment screening approach designed to target specifically the S-adenosyl-l-methionine pocket of catechol O-methyl transferase allowed the identification of structurally related fragments of high ligand efficiency and with activity on the described orthogonal assays. By use of a reliable enzymatic assay together with X-ray crystallography as guidance, a series of fragment modifications revealed an SAR and, after several expansions, potent lead compounds could be obtained. For the first time nonphenolic and small low nanomolar potent, SAM competitive COMT inhibitors are reported. These compounds represent a novel series of potent COMT inhibitors that might be further optimized to new drugs useful for the treatment of Parkinson's disease, as adjuncts in levodopa based therapy, or for the treatment of schizophrenia.

PubMed: 27685665
DOI: 10.1021/acs.jmedchem.6b00927

実験手法

X-RAY DIFFRACTION (2.7 Å)